MXPA03006855A - Metodo para tratar insuficiencia cardiaca cronica y/o niveles elevados de colesterol, utilizando acido 3,5-diyodotiropropionico, y metodo para su preparacion. - Google Patents

Metodo para tratar insuficiencia cardiaca cronica y/o niveles elevados de colesterol, utilizando acido 3,5-diyodotiropropionico, y metodo para su preparacion.

Info

Publication number
MXPA03006855A
MXPA03006855A MXPA03006855A MXPA03006855A MXPA03006855A MX PA03006855 A MXPA03006855 A MX PA03006855A MX PA03006855 A MXPA03006855 A MX PA03006855A MX PA03006855 A MXPA03006855 A MX PA03006855A MX PA03006855 A MXPA03006855 A MX PA03006855A
Authority
MX
Mexico
Prior art keywords
heart failure
cholesterol levels
diiodothyropropionic acid
chronic heart
treat chronic
Prior art date
Application number
MXPA03006855A
Other languages
English (en)
Spanish (es)
Inventor
Steven Goldman
Original Assignee
Univ Arizona
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Arizona filed Critical Univ Arizona
Publication of MXPA03006855A publication Critical patent/MXPA03006855A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MXPA03006855A 2001-01-31 2002-01-31 Metodo para tratar insuficiencia cardiaca cronica y/o niveles elevados de colesterol, utilizando acido 3,5-diyodotiropropionico, y metodo para su preparacion. MXPA03006855A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/774,994 US6534676B2 (en) 2001-01-31 2001-01-31 Method to treat chronic heart failure and/or elevated cholesterol levels using 3,5-diiodothyropropionic acid and method to prepare same
PCT/US2002/003162 WO2002060389A2 (en) 2001-01-31 2002-01-31 Method to treat chronic heart failure and/or elevated cholesterol levels using 3,5-diiodothyropropionic acid and method to prepare same

Publications (1)

Publication Number Publication Date
MXPA03006855A true MXPA03006855A (es) 2004-03-12

Family

ID=25102976

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA03006855A MXPA03006855A (es) 2001-01-31 2002-01-31 Metodo para tratar insuficiencia cardiaca cronica y/o niveles elevados de colesterol, utilizando acido 3,5-diyodotiropropionico, y metodo para su preparacion.

Country Status (7)

Country Link
US (1) US6534676B2 (enExample)
EP (1) EP1432310A4 (enExample)
JP (1) JP2004522747A (enExample)
AU (1) AU2002243801B2 (enExample)
CA (1) CA2436421C (enExample)
MX (1) MXPA03006855A (enExample)
WO (1) WO2002060389A2 (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6716877B2 (en) * 2001-01-31 2004-04-06 The Arizona Board Of Regents On Behalf Of The University Of Arizona Method to treat chronic heart failure and/or elevated cholesterol levels
US7504435B2 (en) * 2001-01-31 2009-03-17 The Arizona Board Of Regents On Behalf Of The University Of Arizona Method for stimulating weight loss and/or for lowering triglycerides in patients
US9198887B2 (en) 2003-09-15 2015-12-01 Nanopharmaceuticals Llc Thyroid hormone analogs and methods of use
US8668926B1 (en) 2003-09-15 2014-03-11 Shaker A. Mousa Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations thereof
AU2004273986B2 (en) * 2003-09-15 2010-04-22 Nanopharmaceuticals Llc Thyroid hormone analogs and methods of use in angiogenesis
US8071134B2 (en) * 2003-09-15 2011-12-06 Ordway Research Institute, Inc. Thyroid hormone analogs and methods of use
EP2428516A1 (en) * 2003-11-19 2012-03-14 Metabasis Therapeutics, Inc. Novel phosphorus-containing thyromimetics
CA2583410A1 (en) * 2004-09-15 2006-03-23 Albany College Of Pharmacy Thyroid hormone analogs for promoting angiogenesis
US20090232879A1 (en) 2005-05-26 2009-09-17 Metabasis Therapeutics, Inc. Thyromimetics for the Treatment of Fatty Liver Diseases
RU2007148927A (ru) * 2005-05-26 2009-07-10 Метабэйзис Терапьютикс, Инк. (Us) Новые тиреомиметики, содержащие фосфиновую кислоту
US20090022806A1 (en) * 2006-12-22 2009-01-22 Mousa Shaker A Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists and formulations and uses thereof
US10130686B2 (en) 2005-09-15 2018-11-20 Nanopharmaceuticals Llc Method and composition of thyroid hormone analogues and nanoformulations thereof for treating inflammatory disorders
US9498536B2 (en) 2005-09-15 2016-11-22 Nanopharmaceuticals Llc Method and composition of thyroid hormone analogues and nanoformulations thereof for treating anti-inflammatory disorders
WO2007035612A2 (en) 2005-09-16 2007-03-29 Ordway Research Institute, Inc. Polyphenol conjugates as rgd-binding compounds and methods of use
EP2120913B1 (en) * 2006-12-22 2015-01-21 NanoPharmaceuticals LLC Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations and uses thereof
AU2008219585A1 (en) * 2007-02-27 2008-09-04 The Arizona Board Of Regents On Behalf Of The University Of Arizona Administration of 3,5-diiodothyropropionic acid for stimulating weight loss, and/or lowering triglyceride levels, and/or treatment of metabolic syndrome.
JPWO2009028608A1 (ja) * 2007-08-31 2010-12-02 三菱瓦斯化学株式会社 オルト位がヨウ素置換されたフェノール誘導体の製造方法
WO2010075332A1 (en) * 2008-12-23 2010-07-01 Charitable Leadership Foundation Small molecule ligands of the integrin rgd recognition site and methods of use
US9180107B2 (en) * 2009-03-31 2015-11-10 Nanopharmaceuticals Llc Combination treatment of cancer with cetuximab and tetrac
WO2010148007A2 (en) 2009-06-17 2010-12-23 Ordway Research Institute, Inc. Nanoparticle and polymer formulations for thyroid hormone, analogs, antagonists, and formulations and uses thereof
US8802240B2 (en) 2011-01-06 2014-08-12 Nanopharmaceuticals Llc Uses of formulations of thyroid hormone analogs and nanoparticulate forms thereof to increase chemosensitivity and radiosensitivity in tumor or cancer cells
WO2015120458A1 (en) * 2014-02-10 2015-08-13 Fred Hutchinson Cancer Research Center Halogen treatment of heart attack and ischemic injury
AU2017279536A1 (en) 2016-06-07 2018-12-20 Nanopharmaceuticals, Llc Non-cleavable polymer conjugated with αvβ3 integrin thyroid antagonists
WO2018094265A2 (en) 2016-11-21 2018-05-24 Viking Therapeutics, Inc. Method of treating glycogen storage disease
AU2018280118B2 (en) 2017-06-05 2021-07-15 Viking Therapeutics, Inc. Compositions for the treatment of fibrosis
EA202091979A1 (ru) 2018-03-22 2021-06-22 Вайкинг Терапьютикс, Инк. Кристаллические формы и способы получения кристаллических форм соединения
US10328043B1 (en) 2018-04-11 2019-06-25 Nanopharmaceuticals, Llc. Composition and method for dual targeting in treatment of neuroendocrine tumors
US11351137B2 (en) 2018-04-11 2022-06-07 Nanopharmaceuticals Llc Composition and method for dual targeting in treatment of neuroendocrine tumors
EP4775207A2 (en) 2018-12-05 2026-07-15 Viking Therapeutics, Inc. Compositions for the treatment of fibrosis
US10961204B1 (en) 2020-04-29 2021-03-30 Nanopharmaceuticals Llc Composition of scalable thyrointegrin antagonists with improved blood brain barrier penetration and retention into brain tumors
EP4161925A4 (en) 2020-06-09 2024-09-04 Viking Therapeutics, Inc. COMPOSITIONS AND METHODS FOR THE TREATMENT OF LIVER DISEASES
US11723888B2 (en) 2021-12-09 2023-08-15 Nanopharmaceuticals Llc Polymer conjugated thyrointegrin antagonists
JP2025522112A (ja) 2022-07-11 2025-07-10 プリズム・エルエルシー アラン・ハーンドン・ダドリー症候群を治療するための方法
CA3261860A1 (en) * 2022-07-11 2024-01-18 Dexcel Pharma Technologies Ltd. METHODS AND FORMULATIONS FOR THE PRENATAL TREATMENT OF ALLAN-HERNDON-DUDLEY SYNDROME
WO2024015764A1 (en) * 2022-07-11 2024-01-18 PriZm, LLC 3,5-diiodothyropropionic acid compositions and methods of use thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US812140A (en) * 1901-06-14 1906-02-06 Perry E Kent Gun-barrel for pistols, rifles, and ordnance.
US2803654A (en) 1955-06-24 1957-08-20 Baxter Laboratories Inc Preparation of thyroxine products
DE1078582B (de) * 1958-10-29 1960-03-31 Hoechst Ag Verfahren zur Herstellung substituierter Thyropropionsaeuren
US3102136A (en) * 1959-06-24 1963-08-27 Warner Lambert Pharmaceutical Process of preparing diiodinated analogs of thyronine
US3149153A (en) * 1961-12-05 1964-09-15 Smith Kline French Lab 3'-substituted-3, 5-diiodothyronine and salts thereof
US5158978A (en) 1990-02-05 1992-10-27 British Technology Group (U.S.A.) Thyroid hormone treatment of acute cardiovascular compromise
US5331000A (en) * 1992-03-09 1994-07-19 Sepracor Inc. Antipyretic and analgesic methods and compositions containing optically pure R(-) ketoprofen
WO1993017680A1 (en) * 1992-03-13 1993-09-16 Sepracor, Inc. Antipyretic and analgesic methods and compositions containing optically pure r-etodolac
US5284971A (en) 1992-07-16 1994-02-08 Syntex (U.S.A.) Inc. 4-(3-cyclohexyl-4-hydroxy or-methoxy phenylsulfonyl) 3,5 dibromo phenyl acetic thyromimetic cholesterol-lowering agents
US5981592A (en) * 1995-03-13 1999-11-09 Loma Linda University Medical Center Method and composition for treating cystic fibrosis
US5883294A (en) 1997-06-18 1999-03-16 The Regeants Of The University Of California Selective thyroid hormone analogs

Also Published As

Publication number Publication date
EP1432310A2 (en) 2004-06-30
CA2436421C (en) 2011-06-14
CA2436421A1 (en) 2002-08-08
EP1432310A4 (en) 2006-06-21
US6534676B2 (en) 2003-03-18
US20020151594A1 (en) 2002-10-17
WO2002060389A3 (en) 2004-04-15
AU2002243801B2 (en) 2006-12-07
WO2002060389A2 (en) 2002-08-08
JP2004522747A (ja) 2004-07-29

Similar Documents

Publication Publication Date Title
WO2002060389A3 (en) Method to treat chronic heart failure and/or elevated cholesterol levels using 3,5-diiodothyropropionic acid and method to prepare same
BR0212252A (pt) Métodos para reduzir a hipertensão e a insuficiência cardìaca em um mamìfero
HRP20040352B1 (en) Use of flibanserin in the treatment of sexual disorders
ATE355374T1 (de) Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen
SV1995000007A (es) Derivados del acido micofenolico 5-substituidos.
SG158731A1 (en) Novel medicament compositions, based on anticholinergically effective compounds and beta-mimetics
DE602004027936D1 (de) Tocopherolmodifizierte therapeutische arzneimittelverbindung
WO2003092584A3 (en) Agents which regulate, inhibit, or modulate the activity and/or expression of connective tissue growth factor (ctgf) as a unique means to both lower intraocular pressure and treat glaucomatous retinopathies/optic neuropathies
CY1109191T1 (el) Μια νεα χρηση της δεφεριπρονης
EP1251126A3 (en) Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation
ATE239474T1 (de) Verwendung von levobupivacain
BR0111591A (pt) Compostos, composição farmacêutica, e, métodos para elevar o nìvel de plasma do hormÈnio de crescimento em um mamìfero, para o tratamento de deficiência da secreção do hormÈnio de crescimento, para o tratamento do retardo do crescimento em crianças, para o tratamento de distúrbios metabólicos associados com a deficiência da secreção do hormÈnio de crescimento, em particular em pacientes idosos, e para promover a cura de ferimentos, recupeção de cirurgia ou recuperação de doenças debilitantes
CY1111396T1 (el) Ρινικη χορηγηση μετοκλοπραμιδης για την αγωγη της γαστροπαρεσης
PA8467401A1 (es) Procedimiento para tratar la insuficiencia cardiaca
WO2003092617A3 (en) Combinations for the treatment of inflammatory skin disorders
CY1108105T1 (el) Ιβανδρονικο οξυ για την θεραπευτικη αντιμετωπιση και την προληψη της οστεoπορωσης
DE60137635D1 (de) Verwendung von allopurinol zur behandlung von bluthochdruck
ES2168766T3 (es) Preparacion farmaceutica que incluye el propeptido vwf.
ATE202483T1 (de) Immuntolerante prothrombinkomplex-präparation
NO20014241D0 (no) C16-umettede FP-selektive prostaglandinanaloger
DK0846173T3 (da) Anvendelse af et anti-interleukin-9-antistof til fremstilling af et lægemiddel til behandling af astma
ATE419346T1 (de) Hemmung der bildung von atherosklerotischen wunden mittels afabp antisens nukleinsäuren
MX9403032A (es) Quinolil-dihidropiridinas condensadas, procedimiento para su fabricacion ysu uso en medicamentos.
DK1596879T3 (da) Anvendelse af kahalalidforbindelser til fremstilling af et medikament til behandling af psoriasis
ITTO20000441A0 (it) Composizione terapeutica per la cura della psoriasi.

Legal Events

Date Code Title Description
FG Grant or registration